Share Twitter LinkedIn Facebook Email Fredrik Schjesvold, MD of Oslo University College addresses how this affects clinicians and what is next for research.
53 vs 31 Month Isatuximab-VRD Results: My Interview with SANOFI’s Global Product Head at ASCO 2024 ASCO Annual Meeting 2 Mins Read
